Quick Answer
Ovid Therapeutics Inc. reported Total Revenue of $7.25 million for the year ending 2025.
- Ovid Therapeutics Inc. showed an increase of +1,181.3% in Total Revenue from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $1.45 million | Q2 2022: $0.00 | Q3 2022: $11.1 thousand | Q1 2023: $66.0 thousand | Q2 2023: $75.0 thousand | Q3 2023: $109.0 thousand | Q1 2024: $148.0 thousand | Q2 2024: $169.0 thousand | Q3 2024: $173.0 thousand | Q1 2025: $130.0 thousand | Q2 2025: $6.27 million | Q3 2025: $132.0 thousand.
- Over the full 5 years of available data (2021 to 2025), Ovid Therapeutics Inc.'s Total Revenue has declined by 96.5%.
- Historical annual values: Fiscal year 2025: $7.25 million | Fiscal year 2024: $566.0 thousand | Fiscal year 2023: $392.0 thousand | Fiscal year 2022: $1.50 million | Fiscal year 2021: $208.38 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: